Evaluation of the effect of desloratadine in the treatment of acne

Phase 3

Recruiting

• Conditions: Acne vulgaris.; Acne vulgaris; L70.0

• Registration Number: IRCT20211010052723N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 November 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patient consent to participate in the study
Age over 15 years
No history of allergy to retinoid compounds
Do not take oral medications to treat acne for the past 2 months

Exclusion Criteria

liver or kidney disease and dyslipidemia
pregnancy or desire to get pregnant
breastfeeding

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Acne Score with GAGS (Global Acne Grading System). Timepoint: Evaluation of acne lesions before receiving the drug and at weeks 8, 16 and 24. Method of measurement: In the Global Acne Grading System 19 to 30 are considered moderate, 31-38 severe and above 38 very severe.;Evaluation of the side effects of isotretinoin [dry skin, lips (Mild, moderate and severe), dry eyes, nosebleeds, and hair loss]. Timepoint: at weeks 8, 16 and 24. Method of measurement: Asking the patients.